drugset / Trial / NCT02341417
Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study was to characterize the long-term safety and tolerability of cinacalcet in pediatric patients with chronic kidney disease (CKD) receiving dialysis.
Timeline
- Start
- 2015-06-10
- Primary completion
- 2017-03-15
- Completion
- 2017-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cinacalcet | Other / unclassified | 1 mg | — |
| Subject | Cinacalcet | Other / unclassified | 2.5 mg | — |
| Subject | Cinacalcet | Other / unclassified | 5 mg | — |
| Subject | Cinacalcet | Other / unclassified | 7.5 mg | — |
| Subject | Cinacalcet | Other / unclassified | 10 mg | — |
| Subject | Cinacalcet | Other / unclassified | 15 mg | — |
| Subject | Cinacalcet | Other / unclassified | 30 mg | — |
| Subject | Cinacalcet | Other / unclassified | 60 mg | — |
| Subject | Cinacalcet | Other / unclassified | 90 mg | — |
| Subject | Cinacalcet | Other / unclassified | 120 mg | — |
| Subject | Cinacalcet | Other / unclassified | 180 mg | — |